Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD ...
November 03, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
October 28, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
October 27, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to...
September 17, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic...
September 03, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
August 27, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
August 11, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b...
August 04, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
June 26, 2025 23:56 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...